Scientific Heritage
From molecular imaging research to a clinical-stage uPAR radiopharmaceutical platform.
Curasight originates from more than a decade of research at Rigshospitalet, Copenhagen University Hospital, and the University of Copenhagen.
Research
Molecular imaging research
The scientific work, led by Professor Andreas Kjær and undertaken by his team, focused on molecular imaging, peptide radioligands and the role of uPAR in cancer invasion and metastasis.
First-in-human PET imaging
The AE105 based peptide radiopharmaceuticals were developed to bind uPAR and were translated from preclinical research into first-in-human PET imaging.
Nine clinical studies
Subsequently, nine clinical studies including more than 500 patients evaluated uPAR PET across eight solid tumor types, building the human evidence base that now supports Curasight’s therapeutic strategy.
Scientific Heritage
Curasight was established in 2013 to advance this science commercially.
The company listed on Spotlight Stock Market in 2020, entered a prostate cancer diagnostic license relationship with Curium in 2023 covering an ongoing phase 2 trial in prostate cancer.
The company dosed the first patient in the current glioblastoma Phase 1 uTREAT® program in December 2025.
Listed on Spotlight Stock Market
License relationship with Curium
First patient dosed in the glioblastoma Phase 1 uTREAT® program
More about Curasight
About us
A focused team combining radiopharmaceutical science, clinical development and company building.
About us
Board experience spanning biotechnology, radiopharmaceuticals, oncology, drug development, transactions and capital markets.
About us
To target the biology that makes cancer aggressive.